Compare H2O America (HTO) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
H2O America vs State Street SPDR S&P Biotech ETF — how do they compare? H2O America trades at $64.61 (market cap $2.70B), while State Street SPDR S&P Biotech ETF trades at $151.8. The key difference: H2O America pays a 2.73% dividend while State Street SPDR S&P Biotech ETF pays none, and H2O America is trading nearer its 52-week high, State Street SPDR S&P Biotech ETF nearer its low. Which is the better fit depends on your goals.
| HTO | XBI | |
|---|---|---|
Market Cap | $2.70B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $65.43 | $164.28 |
52-Week Low | $44.44 | $85.16 |
Enterprise Value | $4.42B | — |
Dividend Yield | 2.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HTO trades at $64.52, down 1.39% today, with strong technical indicators showing a bullish trend. The company maintains solid fundamentals with 12.87% net income margin and consistent earnings beats in recent quarters. Recent news highlights upcoming Q2 2026 earnings report on July 27, 2026, and institutional buying activity. Technical analysis shows support at $62-$64 with resistance at $65-$66 levels.
HTO presents a balanced investment case with 80% analyst buy ratings and a $63.50 consensus target. The water utility's stable revenue streams and dividend yield provide defensive characteristics, though valuation multiples appear full and RSI levels suggest near-term overbought conditions. Execution on $2.7 billion capex plan remains key for growth.
XBI, the SPDR S&P Biotech ETF, trades at $150.94, down 2.14% today amid a bearish technical signal. The ETF holds 155 biotech stocks equally weighted, offering high beta exposure. Recent news highlights a 17% monthly surge driven by AI drug discovery and M&A activity, though analyst consensus remains a lone Hold rating. Key support sits at $151 with resistance at $155.
Outlook hinges on biotech sector momentum from innovation and deal flow, but risks include volatility from small-cap holdings and regulatory uncertainty. The neutral sentiment and lack of fundamental ratios suggest investors await clearer earnings trends from underlying holdings for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About H2O America
H2O America is a utility company that provides essential water and wastewater services, primarily in the United States. The company operates a network of regulated water and wastewater systems, focusing on responsible resource management and high-quality service delivery. HTO aims to expand its operational footprint through acquisitions and internal growth, serving residential, commercial, and industrial customers.
Read more on HTO →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
